Drug Pricing Scrutiny Intensifies

Increased scrutiny is being placed on pharmacy benefit managers (PBMs) and the overall structure of drug pricing. A deeper understanding of the industry reveals systemic issues that protect current pricing models. This heightened attention suggests potential regulatory changes or market pressures aimed at addressing concerns about the affordability and accessibility of prescription medications, impacting pharmaceutical companies and PBMs.